Alicanto® is Abterra Biosciences’ proprietary antibody discovery platform that mines the entire immune response to identify diverse, functional antibodies. For an overview of the proteogenomic process, read more about Alicanto®.

• The infographic below was created using Alicanto’s analysis of llama immune response to immunization.

Tell Us About Your Project

Related Resources

Watch the full presentation: “Next-Generation Repertoire Sequencing for Mining Single Domain Antibodies” that was given by our CSO, Stefano Bonissone, at the PEGS Boston Virtual Summit 2021.

With Alicanto® you see not just the diverse candidates selected by our platform, but any relative of the candidates found in the BCR repertoire. Read more on our recent work – Clonal Hit-Expansion Case Study.